Related Experiment Video

Updated: May 10, 2026

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
04:33

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive

Gualberto Ruaño1, Bonnie L Szarek, David Villagra

  • 1Genetics Research Center, Hartford Hospital, 67 Jefferson Street, Hartford, CT 06106, USA.

Biomarkers in Medicine
|June 6, 2013
PubMed

Insights

The CYP2D6 genotype significantly impacts major depressive disorder treatment length. Patients with deficient CYP2D6 metabolizers experienced longer hospital stays, affecting treatment outcomes and costs.

Area of Science:

  • Pharmacogenomics
  • Psychiatric Medicine
  • Clinical Pharmacology

Background:

  • Major depressive disorder (MDD) treatment length is influenced by various factors.
  • Genetic variations, particularly in drug-metabolizing enzymes like CYP2D6, can affect drug efficacy and patient response.
  • Understanding these genetic influences is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To investigate the association between CYP2D6 genotype and hospitalization duration in MDD patients.
  • To determine if CYP2D6 metabolic status influences treatment length.

Main Methods:

  • Genotyping of 149 MDD inpatients for CYP2D6 altered alleles.
  • Quantitative assessment of drug metabolism indices (metabolic reserve, alteration).
  • Statistical analysis of the relationship between CYP2D6 status and length of hospital stay.

Main Results:

  • Hospital stays were significantly longer for patients with deficient CYP2D6 metabolizers (metabolic reserve <2) compared to functional or suprafunctional metabolizers (metabolic reserve ≥2).
  • Average hospital stay was 7.8 days for deficient metabolizers versus 5.7 days for others (p = 0.002).

Conclusions:

  • CYP2D6 enzymatic functional status significantly impacts hospital stay duration in MDD patients.
  • This effect may be due to altered drug efficacy or increased side effects of CYP2D6-metabolized medications.
  • Functional scoring of CYP2D6 alleles can improve psychiatric treatment quality, patient satisfaction, and economic efficiency.
Abstract

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...